Oxford University Innovation

University of Oxford and Oracle Cloud System Helping Researchers Identify COVID-19 Variants Faster

Monday, September 20, 2021 - 8:00am

Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent.

Key Points: 
  • Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent.
  • The Global Pathogen Analysis System is being provided as a free resource to help combat COVID-19 and other microbial health threats.
  • Researchers are using the system to upload pathogen data and receive comprehensive results within minutes.
  • Oracle offersintegrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.For more information about Oracle (NYSE: ORCL), please visit us at oracle.com .

Legend Capital Led a New Round of Investment of Etana

Tuesday, September 14, 2021 - 12:42am

HONG KONG, Sept 14, 2021 - (ACN Newswire) - Legend Capital led a new round of investment of PT Etana Biotechnologies Indonesia (Etana), along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM).

Key Points: 
  • HONG KONG, Sept 14, 2021 - (ACN Newswire) - Legend Capital led a new round of investment of PT Etana Biotechnologies Indonesia (Etana), along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM).
  • Hong Tan, Managing Director of Legend Capital, said "We appreciate Etana's vision to provide Indonesia with cost-effective biopharmaceuticals.
  • Legend Capital is an independent professional venture capital company under Legend Holdings.
  • Its core business is positioned at the initial stage of venture capital and expansion stage growth investment.

Vaccitech to Present at Upcoming September Investor conferences

Thursday, September 9, 2021 - 1:00pm

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer.

Key Points: 
  • Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer.
  • The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Thursday, August 12, 2021 - 1:00pm

OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the Companys recent corporate developments.
  • The second quarter of 2021 was our first as a public company following our initial public offering that closed in May, said Bill Enright, CEO of Vaccitech.
  • We continue to make significant progress across all of our ongoing programs, including the recent announcement of our clinical collaboration with Arbutus.
  • Second Quarter 2021 Financial Highlights:
    Cash position: As of June 30, 2021, cash and cash equivalents were $243.6 million, compared to $43.3 million as of December 31, 2021.

openbusinesscouncil and University of Oxford's TMCD To Co-Organise the International Investment and Innovation Forum on June 25

Tuesday, June 22, 2021 - 6:00pm

Taking place at the end of the month, and co-organised by openbusinesscouncil , the Forum will bring together a rich ecosystem of thought leaders, tech innovators and business magnates.

Key Points: 
  • Taking place at the end of the month, and co-organised by openbusinesscouncil , the Forum will bring together a rich ecosystem of thought leaders, tech innovators and business magnates.
  • The Forum will end with a talk from Chris Fellingham, Licensing & Ventures Manager at Oxford University Innovation.
  • OxValue.AI aims to facilitate the transfer of technology to developing countries as well as fund research within TMCD (Oxford).
  • Professor Xiaolon Fu will introduce OxValue.AI while Professor Yu Xiong, Associate Dean International at Surrey University, presides over the launch and MoU signing.

Medidata and Oxford University Innovation’s Clinical Outcomes Team Announce Addition of Gold Standard Questionnaires to eCOA Library

Thursday, November 12, 2020 - 10:00am

Minimizing the time required to properly deploy COA instruments (or questionnaires or surveys) within an eCOA study system is a key benefit for any clinical trial sponsor.

Key Points: 
  • Minimizing the time required to properly deploy COA instruments (or questionnaires or surveys) within an eCOA study system is a key benefit for any clinical trial sponsor.
  • Medidata has seen hours of work reduced by more than 50 percent in some cases when using questionnaires from the eCOA library.
  • Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systmes.
  • Clinical Outcomes, part of Oxford University Innovation (a UK-based company) and solely owned by the University of Oxford, specialises in the management and support of high-quality Clinical Outcome Assessments.

Language Scientific and Clinical Outcomes at Oxford University Innovation Announce Collaboration for Translation, Linguistic Validation and COA Management Services

Wednesday, June 10, 2020 - 4:00pm

MEDFORD, Mass., June 10, 2020 /PRNewswire-PRWeb/ --Language Scientific, Inc., the leading medical and scientific translation company, is pleased to announce a new innovative collaboration with Oxford University Innovation Ltd, the premier provider of Clinical Outcome Assessment (COA) management services.

Key Points: 
  • MEDFORD, Mass., June 10, 2020 /PRNewswire-PRWeb/ --Language Scientific, Inc., the leading medical and scientific translation company, is pleased to announce a new innovative collaboration with Oxford University Innovation Ltd, the premier provider of Clinical Outcome Assessment (COA) management services.
  • The Clinical Outcomes Team at Oxford University Innovation (The University of Oxford's wholly owned technology transfer company) specializes in the dedicated, world class professional management of COA Instruments.
  • Oxford University Innovation is collaborating with Language Scientific to provide linguistic validation and translation services because of LS' extensive experience and highest quality reputation in assisting clinical, medical and scientific organizations.
  • Language Scientific is always looking to collaborate with highly respected organizations that put quality first such as Oxford University Innovation.